|
HS Code |
195014 |
| Product Name | HIFULL HL-300 Colloidal Silica (Pharma Grade) |
| Appearance | Milky white liquid |
| Silica Content | 30% ± 1% |
| Particle Size | 7-16 nm |
| Ph | 9.0 - 10.5 |
| Stabilizer | Sodium |
| Density | 1.20 ± 0.05 g/cm³ |
| Viscosity | <10 mPa.s (25°C) |
| Solvent | Water |
| Application | Pharmaceutical excipient |
| Storage Temperature | 5-35°C |
| Shelf Life | 12 months |
| Packaging | 25 kg/plastic drum |
As an accredited HIFULL HL-300 Colloidal Silica (Pharma Grade) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | HIFULL HL-300 Colloidal Silica (Pharma Grade) is packaged in a 25 kg high-density polyethylene (HDPE) drum with secure sealing. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL): 20 pallets, each with 36 x 30L drums, totaling 720 drums (21.6 metric tons net weight). |
| Shipping | **Shipping Description for HIFULL HL-300 Colloidal Silica (Pharma Grade):** HIFULL HL-300 Colloidal Silica (Pharma Grade) is shipped in secure, leak-proof containers (typically 25 kg drums or 1000 kg IBCs), clearly labeled and compliant with international regulations. Protect from freezing and direct sunlight during transit. Ensure upright positioning. Handle with care to avoid spillage or contamination. |
| Storage | **HIFULL HL-300 Colloidal Silica (Pharma Grade)** should be stored in a tightly sealed container, in a cool, dry, and well-ventilated area, away from direct sunlight and sources of heat or ignition. Protect from freezing and contamination. Avoid storing near incompatible substances, such as strong acids or bases. Follow all relevant safety and handling guidelines for silica-based materials. |
| Shelf Life | HIFULL HL-300 Colloidal Silica (Pharma Grade) typically has a shelf life of 12 months when stored in tightly sealed original containers. |
Applications of HIFULL HL-300 Colloidal Silica (Pharma Grade) in Industrial ManufacturingHIFULL HL-300 Colloidal Silica (Pharma Grade) supports advanced manufacturing requirements across the pharmaceutical and life science sectors. Its chemical purity and controlled particle size distribution directly meet the technical specifications of customers operating in regulated industrial environments. Below are several established applications with proven downstream integration, real compliance needs, technical process details, and finished product outputs.
Tablet manufacturers rely on colloidal silica as a glidant and anti-caking agent during direct compression of powders. In high-speed production lines, HL-300 reduces inter-particulate friction, enabling reliable die-filling with cohesive APIs and excipients while maintaining product integrity. Its pharmaceutical grade assures secure inclusion without the risk of contamination, supporting consistent tablet weight and uniformity in both generic and proprietary solid dosage forms. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of sterile parentals incorporate colloidal silica to stabilize aqueous and non-aqueous suspensions for injectable drug products. HL-300’s controlled particle size and high-purity matrix prevent agglomeration of API particles, providing homogeneous dispersion and reducing sedimentation rates throughout vial and ampoule shelf life. The production environment requires stringent microbiological control, which this grade supports due to validated low endotoxin levels and minimal bioburden. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Wet granulation lines utilize HL-300 as an effective binder and rheology modifier for high-potency and moisture-sensitive active pharmaceutical ingredients (APIs). Its sub-micron size ensures binding without altering pharmacokinetics or causing API precipitation, especially during rapid solvent evaporation or spray granulation. The pharmaceutical grade prevents cross-contamination, aligning with regulatory batch release and traceability systems required for regulated molecule handling. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Colloidal silica enhances aqueous and solvent-based coating systems for oral pills and capsules by minimizing tackiness and supporting even film layering. HL-300’s uniform morphology provides effective particulate dispersion, reducing agglomeration during pan or fluid-bed coating. This supports strict environmental controls on solvent recovery and dust by enabling reliable, continuous membrane formation even during high-throughput operations. Specified grades ensure compliance with film-forming excipients and colorant regulations. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Colloidal silica serves as a precursor for making advanced silica gel used in preparative and process chromatography. When producing stationary phase supports for liquid chromatography, HL-300 provides a consistent nano-silica feedstock for controlled gel synthesis. The resulting packing materials exhibit finely tuned surface area, pore size, and mechanical strength, meeting both regulatory and technical standards for large-scale pharmaceutical purification, including antibody and hormone API separation. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of pharmaceutical suspensions and syrups use HL-300 to control flow, prevent sedimentation, and stabilize suspensions for pediatric and geriatric oral dosage forms. This colloidal silica grade can be incorporated in sugar-free or high-sugar matrices without affecting solubility or taste. It supports precise viscosity modification, especially important for multi-dose syrups stored in varying climatic conditions. All additions undergo risk assessment and full traceability checks according to GMP batch protocols. Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
|
Competitive HIFULL HL-300 Colloidal Silica (Pharma Grade) prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
We have spent many years on the production floor, controlling every detail and refining every process for colloidal silica. HIFULL HL-300 grew out of that hands-on experience. This is not another off-the-shelf option — our pharmaceutical grade colloidal silica answers real needs that crop up during scale-up, blending, tablet coating, and beyond. From the first step to finished batch, we weigh each decision by how it affects performance, reproducibility, and the safety of the final drug.
Every batch of HL-300 starts with an unwavering commitment to purity. Through on-site deionization and filtration, we remove ions and particulate contaminants that can send a production lot off-spec. HL-300 delivers a consistent narrow particle size profile, with average diameters controlled in nanometers, which impacts both flow and dispersibility during tableting or liquid formulation. For pharmaceutical production, even minor variability can lead to major downstream issues — we designed HL-300 from the ground up to stay steady from batch to batch, so a process developed today will match tomorrow’s runs.
We manufacture in controlled facilities that focus only on high-purity colloidal silicas. Many other “pharma” grades in the market are re-labeled industrial grades, but our HL-300 never shares lines with products destined for abrasive or industrial slurry use. We avoid introducing cross-contamination sources at every step.
HL-300 steps up where other flow aids fall short. Small, spherical silica particles serve as anti-caking agents, glidants, or tablet coating additives. In direct compression, HL-300’s surface area and electrostatic properties help the powder move smoothly and fill dies evenly, cutting down on weight variation and broken tablets. During process development, chemists have found that HL-300 allows faster run speeds, fewer flow interruptions, and better weight control with smaller excipient loads.
For tablet coating, HL-300 acts as a stabilizer for film-forming solutions, dispersing evenly in both aqueous and solvent-based systems. Poorly dispersed silica can ruin a coating run — HL-300 disperses quickly with modest agitation, avoiding agglomeration that causes surface defects or roughness. As a result, you get a reliable, smooth coating and repeatable appearance from lot to lot.
Formulators often face tough compromises when picking excipients. HL-300 offers real flexibility for developing both wet and dry dosage forms. We have adjusted the surface chemistry so it wets easily, but does not clump in high-speed mixers or during high-shear granulation. This makes it suitable for granulation, roller compaction, even spray drying. The narrow size distribution reduces the risk of segregation — HL-300 stays mixed, so actives distribute more evenly throughout the batch.
With HL-300, labs working in both small-scale R&D and large-scale production see the same performance, so there is no nasty surprise during transfer to full-scale. Process stability is not just marketing speak; it is baked into how we build and audit HL-300. In practice, this means a process that runs smoothly one day will do so the next.
Many so-called pharma grade colloidal silicas come as a downgrade from paints or ceramics. Our manufacturing lines for HL-300 have dedicated pharma-grade starting materials and maintain stricter controls on microbial and trace metal levels. Routine testing confirms that the product exceeds limits for heavy metals and residual solvents imposed by pharmacopeia standards. It is not enough to pass tests once for a certificate: each production run faces scrutiny in our in-house and third-party audits.
General-purpose colloidal silicas lack our tight controls on silanol group density, sodium content, and surface charge balance. HL-300’s controlled chemistry means fewer unexpected interactions with APIs or other excipients, translating to less rework and fewer deviations during both process development and routine release.
We do not use excuses about variability in raw material. Our team knows precisely where each component originates, and trace every drum back through records for raw water quality, silicate purity, and filter integrity. During each lot’s manufacture, we run real-time particle sizing, solid content, viscosity, and pH measurements — not just spot checks, but full-batch monitoring. Statistical process control guides each adjustment, and we hold every batch until multiple QC personnel, not just one, have signed off on conformity with our pharmacopeia-based specifications.
Customers rely on us because they have lived the pain of rejected pharmaceutical lots due to surprises in excipient quality. HL-300’s track record for approved releases reflects our refusal to cut corners or obscure out-of-spec product with paperwork sleight-of-hand.
Since introducing HL-300 to the pharmaceutical market, we have visited customer sites across dozens of countries. Our technical team partners with process development scientists to adjust mixing protocols, optimize solid loading, and reduce dust formation. HL-300’s stable suspension properties help teams minimize downtime for filter changes or nozzle cleaning in tablet coating. The result is smoother production and fewer deviations logged per batch.
Operations staff using HL-300 note reduced buildup on granulator sweeps and faster equipment cleaning, both safety and efficiency gains. Cutting back on powder residue also reduces cross-contamination risk. Many of our customers now specify HL-300 as standard for formulations with moisture-sensitive actives because it holds low water content and does not disrupt calcium stability, making it compatible with a wide range of excipient packs.
We recognize that excipients, even those used in small amounts, affect the efficacy and safety of finished drugs. HL-300 goes through regular risk assessment and quality review. Our team revisits cleaning batches, storage protocols, and personnel training at least quarterly. Rather than waiting for problems, we visit customer plants to discuss potential improvement areas and gather hands-on feedback for future product upgrades.
In addition to conventional batch reporting, we provide long-term impurity trend data to developers working on regulated markets. This way, teams see not only a snapshot for the next review, but can plan process validation years ahead, anticipating how trends affect long-term stability studies and regulatory compliance.
HL-300 comes as a stable aqueous colloid, making it easy to measure and add to both pilot and commercial-scale blenders or mixing tanks. Operators who have switched from powder-based silica remark on the nearly dust-free operation and the convenience during charge preparation. Pumps and hoses that handled HL-300 do not require extra abrasion-resistant linings. Its low viscosity at typical concentrations allows for transfer through standard peristaltic or diaphragm pumps without causing clogging or foaming issues.
Switching a production line to HL-300 typically takes a few development cycles, but we help every customer plot out blending ratios, dispersion steps, and documentation for audit and validation. Companies find that HL-300 integrates into their records smoothly — not just technically, but in terms of regulatory documentation, including permissible residual levels and supplier auditing.
Drug formulation does not stand still. More processes rely on moisture-sensitive actives or complex combinations requiring dependable excipient function. HL-300 was built for these challenges, with ‘pharma grade’ meaning clear documentation, transparent QC processes, and data to back up every claim. We have eliminated non-essential additives, so HL-300 maintains compatibility with allergens, vegan, or gluten-free labeling requirements.
Process engineers testing the HL-300 bring us feedback on throughput, tablet weight error, and process downtime. We take field results just as seriously as laboratory or theoretical data. With streamlined documentation packages — including stability, photostability, and microbial control reports — HL-300 supports rapid regulatory approval.
Because HL-300 is manufactured in pharma-only environments, cleaning and validation are central to every run. We assign a unique batch number and perform verification at multiple checkpoints: from mixing, filtration, and polymerization to packaging. Before shipment, each batch receives a retention sample, which we keep for several years for traceability.
Our staff train alongside pharmaceutical technologists, learning the real problems faced in tablet and liquid production. This partnership results in tweaks to surface chemistry, concentration, and packaging formats tailored to on-the-ground requirements. Over time, HL-300 has evolved — but always with traceable, audited changes and zero compromise in quality.
Working at a chemical manufacturer, we understand the responsibility that comes with supplying excipients for medicines. We avoid vague batch documents, untraceable origins, or inconsistent supply. HL-300 is always produced under the same rigorous protocols. Our transparency in records, root-cause analyses for deviations, and readiness for on-site audits gives peace of mind to audit teams and quality managers.
Documentation packages for HL-300 include detailed analytical methods, not just summary certificates. We publish ingredient standards, impurity profiles, and records for each process adjustment, so customers receive not just a product, but the whole story behind it. This open-door policy has made HL-300 a regular feature in risk-managed supplier networks, strengthening compliance and trust across multinational and local companies alike.
We take delivery guarantees seriously. Pharmaceutical supply chains face more strain than ever, so our production planning favors conservative safety stocks for HL-300. We ship in tamper-evident, batch-traceable containers of sizes designed for both pilot and commercial output. Advance shipment notifications, detailed shipment records, and accessible technical personnel mean that questions about HL-300 never hang in the air unanswered.
Responsive manufacturing has meant we keep pace with changing regulatory standards for peroxides, metals, and microbial content in pharma excipients. Early adoption of advanced filtration and in-process analytics has protected our customers from recalls or regulatory setbacks. Continuous audit programs and third-party laboratory oversight provide extra margin of safety that customers trust with their critical launches.
Today’s pharmaceutical industry weighs sustainability in every decision. We have integrated water recycling and waste minimization into HL-300 production. Each processing cycle features closed-loop filtration and energy-efficient drying. We track environmental impact both at the plant and back through upstream suppliers, reducing our carbon output and supporting a cleaner industry.
HL-300 packaging comes in recyclable drum formats on request, and bulk shipments use reusable IBCs. Lab and customer feedback has shaped our practices — safer handling, less packaging waste, and regular internal audits ensure that a clean product also means a cleaner process.
Pharmaceutical development faces tougher challenges each year. HL-300 allows developers to focus on creativity, not troubleshooting excipient issues. As the industry pursues new forms, controls, and bioavailability strategies, HL-300 stands ready, with proven results in direct compression, granulation, coating, and oral suspension work.
Cross-functional teams from our plant regularly visit customer sites, gather frontline insights, and use that information to keep HL-300 one step ahead of regulatory and process needs. This ongoing direct exchange between manufacturers — not just marketers, traders, or resellers — anchors HL-300’s position in the pharmaceutical excipient market.
Looking at how HL-300 has changed production lines worldwide, we see the difference that true manufacturing discipline and deep process knowledge bring to the market. HL-300 does not just check boxes for purity and reproducibility; it answers every question a production manager or regulatory auditor would ask about source, performance, and support. From our experience, supplying HL-300 means supporting safer, more dependable pharmaceuticals at scale. We keep our focus on manufacturing, on open records, and on continuous improvement — so that customers can focus on producing reliable, high-quality medicines that make a difference.
